Netarsudil

Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022

Retrieved on: 
Tuesday, April 26, 2022
Health, Science, Pharmaceutical, Research, Optical, DME, Netarsudil, Glaucoma, Aerie Pharmaceuticals, U.S. Securities and Exchange Commission, Security (finance), Regulation of tobacco by the U.S. Food and Drug Administration, Food, Private Securities Litigation Reform Act, Patient, Ocular hypertension, Diabetic retinopathy, Eye, SEC, Forward-looking statement, Conjunctivitis, Duane syndrome, FDA, Industry, IOP, Nature, Pharmaceutical industry, Aerie

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022

Retrieved on: 
Wednesday, April 20, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, DME, Netarsudil, Glaucoma, Aerie Pharmaceuticals, U.S. Securities and Exchange Commission, Security (finance), Regulation of tobacco by the U.S. Food and Drug Administration, Food, Private Securities Litigation Reform Act, Patient, Ocular hypertension, Diabetic retinopathy, Eye, SEC, Forward-looking statement, Conjunctivitis, Duane syndrome, FDA, Industry, IOP, Nature, Pharmaceutical industry, Aerie

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET

Retrieved on: 
Wednesday, April 6, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Duane syndrome, Aerie Pharmaceuticals, Private Securities Litigation Reform Act, DME, Conjunctivitis, Ocular hypertension, Forward-looking statement, Netarsudil, SEC, Diabetic retinopathy, IOP, U.S. Securities and Exchange Commission, Food, Glaucoma, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, Eye, Nature, FDA, Patient, Security (finance), Pharmaceutical industry, Aerie

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

Retrieved on: 
Friday, March 18, 2022
Pharmaceutical, Optical, Health, Other Health, Duane syndrome, Aerie Pharmaceuticals, Company, Private Securities Litigation Reform Act, SVB Leerink, University, Partner, NASDAQ, BofA Securities, Leadership, DME, University of Chicago Booth School of Business, Conjunctivitis, Ocular hypertension, Forward-looking statement, UBS, Netarsudil, SEC, Diabetic retinopathy, Latin honors, School, IOP, U.S. Securities and Exchange Commission, Food, Security (finance), Glaucoma, LLC, Bank, Industry, Business administration, University of Chicago, Medication, Regulation of tobacco by the U.S. Food and Drug Administration, The arts, Aerie, Eye, HSBC, Master of Business Administration, Nature, FDA, Patient, Pharmaceutical industry, Management, Business

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022.
  • He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee.
  • I am pleased to welcome Peter to our leadership team, said Raj Kannan, Chief Executive Officer.
  • I am confident Peter will provide strong leadership and will be an excellent addition to the Aerie team.

Visus Therapeutics Announces Appointment of Eye Care Industry Veteran Julia Williams as Vice President of Clinical and Medical Affairs and Expansion of Irvine Co-Headquarters

Retrieved on: 
Wednesday, March 16, 2022
General Health, Pharmaceutical, Health, Clinical Trials, Therapy, Duane syndrome, Program, University, Presbyopia, Investment, AbbVie, Aerie Pharmaceuticals, Standard of care, Allergan, Inc., Research, Instagram, Netarsudil, View, Glaucoma, LinkedIn, Bausch & Lomb, Marketing, Retina, Pharmaceutical industry, Kerosene, Twitter, Visu, Allergan

Visus Therapeutics Inc., a clinical-stage pharmaceutical company developing innovative ophthalmic therapies to improve vision for people around the world, today announced the appointment of eye care industry veteran Julia Williams as vice president of clinical and medical affairs.

Key Points: 
  • Visus Therapeutics Inc., a clinical-stage pharmaceutical company developing innovative ophthalmic therapies to improve vision for people around the world, today announced the appointment of eye care industry veteran Julia Williams as vice president of clinical and medical affairs.
  • The company also announced the expansion of its Irvine co-headquarters in the University of California-Irvine Research Park, including the establishment of a research and development facility with a state-of-the-art laboratory.
  • The addition of Ms. Williams to the Visus leadership team strengthens Visus capabilities in the design and execution of clinical studies and medical affairs strategy.
  • The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia.

Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Medication, Income, Medicines and Healthcare products Regulatory Agency, MHRA, Glaucoma, Conjunctivitis, Webcast, European Medicines Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, Aerie Pharmaceuticals, IOP, Investment, Security (finance), NASDAQ, ID, Duane syndrome, COVID-19, Industry, Company, Private Securities Litigation Reform Act, Nature, Table, U.S. Securities and Exchange Commission, Review, Humanitarian use licenses, Loss, New Drug Application, Aerie, Eye, Food, Software, Diabetic retinopathy, Health care, Netarsudil, FDA, EMA, Forward-looking statement, Patient, Marketing, Ocular hypertension, NDA, Mission statement, Coronavirus, GAAP, SEC, DME, Pharmaceutical industry, Animal, Bank, House of Santen

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022.
  • These achievements have set Aerie up for success in 2022 and beyond, said Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals.
  • For the fourth quarter 2021, our net cash used in operating activities was $30 million, bringing our full year total of net cash used to just under $100 million.
  • Aerie management will host a live conference call and webcast at 5:00 p.m. Eastern Time today to discuss Aeries financial results and provide a general business update.

Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET

Retrieved on: 
Thursday, February 17, 2022
Oncology, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Patient, DME, Food, Diabetic retinopathy, Aerie Pharmaceuticals, Regulation of tobacco by the U.S. Food and Drug Administration, Conjunctivitis, FDA, Glaucoma, Duane syndrome, Eye, Netarsudil, IOP, Ocular hypertension, Pharmaceutical industry, Baking, Aerie

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • More information about Rhopressa, including the product label, is available at www.rhopressa.com .
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • More information on Aerie Pharmaceuticals is available at www.aeriepharma.com .

Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, December 22, 2021
General Health, Pharmaceutical, Health, Other Health, Medication, Conjunctivitis, Marketing, U.S. Securities and Exchange Commission, Retina, Patient, Private Securities Litigation Reform Act, Humanitarian use licenses, Eye, PGA, Duane syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glaucoma, NASDAQ, Ocular hypertension, Financial compensation, Latanoprost, Industry, SEC, Intellectual property, Forward-looking statement, COVID-19, Diabetic retinopathy, Board, Ophthalmology, Netarsudil, Coronavirus, Aerie Pharmaceuticals, EMA, Company, Research, Employment, Food, Security (finance), Nature, FDA, IOP, Pharmaceutical industry, House of Santen, Aerie

In connection with his acceptance of the position of Chief Executive Officer, and in accordance with the terms of Mr. Kannans employment agreement, Mr. Kannan will receive inducement equity awards with a grant date fair value of $5.5 million in the aggregate.

Key Points: 
  • In connection with his acceptance of the position of Chief Executive Officer, and in accordance with the terms of Mr. Kannans employment agreement, Mr. Kannan will receive inducement equity awards with a grant date fair value of $5.5 million in the aggregate.
  • Aerie has two approved products, two Phase 3-ready programs, and an ongoing research program.
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • Aerie continues to focus on the research and development of additional product candidates and technologies in ophthalmology.

Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

Retrieved on: 
Thursday, December 16, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Infectious Diseases, Clinical Trials, Intellectual property, Ocular hypertension, Board, Aerie Pharmaceuticals, Acquisition, NASDAQ, Medication, Merck, Neurology, Eye, Organization, Forward-looking statement, FDA, Glaucoma, Acromegaly, Conjunctivitis, Diabetic retinopathy, Latanoprost, Growth, Coronavirus, EMA, Nature, U.S. Securities and Exchange Commission, Security (finance), Interview, Â, Netarsudil, COVID-19, Director, SEC, CEO, Research, Marketing, PGA, Duane syndrome, Ophthalmology, Merck Group, Food, Immunology, Company, Private Securities Litigation Reform Act, III, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, IOP, Humanitarian use licenses, Pharming, Pharmaceutical industry, House of Santen, Aerie

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021.
  • On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie.
  • The Aerie team has built an impressive ophthalmology company with an exciting glaucoma franchise that is global in reach and an exciting pipeline of product development candidates that has the potential to create significant value, said Raj Kannan, Chief Executive Officer.
  • Before that, Raj was Chief Commercial Officer at Kiniksa Pharmaceuticals, Ltd. (Kiniksa), where he built the commercial operations, including sales, marketing and business analytics functions.

Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions

Retrieved on: 
Tuesday, December 7, 2021
Pharmaceutical, Health, Optical, SEC, Commonwealth, Board of directors, Conjunctivitis, Director, EMA, Latanoprost, Aerie, PGA, CIS, Forward-looking statement, Glaucoma, Commonwealth of Independent States, Private Securities Litigation Reform Act, Food, Patient, Hotel manager, Industry, Pharming, Diabetic retinopathy, Eye, Field line, Intellectual property, Marketing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Coronavirus, Retina, Investment, U.S. Securities and Exchange Commission, Interim, Security (finance), Ocular hypertension, Nature, IOP, Visual impairment, Medication, Aerie Pharmaceuticals, FDA, Severe cognitive impairment, Humanitarian use licenses, Research, Netarsudil, Ophthalmology, Happiness, Partnership, COVID-19, NASDAQ, III, Pharmaceutical industry

Rhopressa and Rocklatan are approved and being sold in the United States by Aerie.

Key Points: 
  • Rhopressa and Rocklatan are approved and being sold in the United States by Aerie.
  • Both Rhopressa and Rocklatan are also approved in Europe and known as Rhokiinsa and Roclanda, respectively.
  • Additionally, Aerie will be manufacturing these products for Santen using our new manufacturing facility in Ireland.
  • Aerie will be responsible for the manufacture and supply of the products to Santen utilizing its Athlone, Ireland plant.